切换至 "中华医学电子期刊资源库"
高级检索
中华介入放射学电子杂志

中华介入放射学电子杂志 ›› 2020, Vol. 08 ›› Issue (01) : 44 -50. doi: 10.3877/cma.j.issn.2095-5782.2020.01.010

所属专题： 文献；

肿瘤介入

肝癌微波消融术后患者复发的危险因素分析
吕远1,†()   
  1. 1. 014030　内蒙古自治区包头市，包头市肿瘤医院介入治疗科
  • 收稿日期:2019-12-18 出版日期:2020-02-25
  • 通信作者: 吕远

Analysis of risk factors for tumor recurrence after microwave ablation for hepatocellular carcinoma

Yuan Lv1,†()   

  1. 1. Department of Interventional Therapy, Baotou Cancer Hospital, Inner Mongolia Autonomous Region, Baotou 014030, China
  • Received:2019-12-18 Published:2020-02-25
  • Corresponding author: Yuan Lv
  • About author:
    Corresponding author: Lv Yuan, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

吕远. 肝癌微波消融术后患者复发的危险因素分析[J]. 中华介入放射学电子杂志, 2020, 08(01): 44-50.

Yuan Lv. Analysis of risk factors for tumor recurrence after microwave ablation for hepatocellular carcinoma[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2020, 08(01): 44-50.

目的

探讨胆囊切除对行肝癌微波消融（microwave ablation，MWA）患者预后的影响。

方法

72例接受MWA治疗肝癌的患者，分为胆囊切除组（36例）和非胆囊切除组（36例），分析总生存率（overall survival，OS）和无进展生存率（progression free survival，PFS），比较胆囊切除组和非胆囊切除组的预后结果。采用单因素和多因素Cox分析评估总生存率和无进展生存率的潜在危险因素以及比较两组之间的预后。

结果

本研究胆囊切除组纳入36例（50.00%），非胆囊切除组纳入36例（50.00%）。胆囊切除组中位OS为35.55个月（4.20～36.00个月），非胆囊切除组31.19个月（10.80～36.00个月） （P=0.894）。随访结束前，胆囊切除组和非胆囊切除组的死亡率分别为22.22%和22.22%。胆囊切除组1、2、3年累积总生存率分别为91.67%、79.91%、75.71%，非胆囊切除组分别为97.22%、88.72%和73.81%（P=0.97）。胆囊切除组中位PFS为7.67个月（1.68～32.30个月），非胆囊切除组为18.25个月（2.24～33.60个月） （P<0.01）。随访结束时，胆囊切除组和非胆囊切除组肝癌复发率分别为69.44%和91.67%，胆囊切除组1、2、3年累积无进展生存率分别为36.11%、16.67%、0.00%，非胆囊切除组分别为77.78%、46.89%和0.00%。非胆囊切除组的累积无进展生存率明显高于胆囊切除组（P<0.01）。多因素分析显示肿瘤数量为3（HR=18.91，95%CI：1.54～232.99，P=0.02）是与OS相关的独立危险因素。多因素分析显示胆囊切除术（HR=3.55，95%CI：1.74～7.26，P<0.01），肿瘤数量为2和3（HR=2.21，95%CI：1.10～4.42，P=0.02；HR=3.63，95%CI：1.26～10.45，P=0.02）和AFP≥400 ng/mL（HR=0.43，95%CI：0.19～0.98，P<0.05）是与PFS相关的独立危险因素。

结论

肝细胞癌患者在MWA后行胆囊切除术后更易发生肝内复发，这可能与γ-GT水平升高有关，且复发率随时间增加而增加。

关键词: 肝癌, 微波消融, 胆囊切除, 预后分析
Objective

To investigate the affect of cholecystectomy on the prognosis of patients underwent microwave ablation (MWA) of hepatocellular carcinoma.

Methods

Seventy-two patients with hepatocellular carcinoma receiving microwave ablation were divided into the cholecystectomy group (n=36) and the non-cholecystectomy group (n=36). The overall survival rate (OS) and progression-free survival rate (PFS) were analyzed to the prognosis of the cholecystectomy group and the non-cholecystectomy group. Univariate and multivariate Cox analyses were used to assess potential risk factors for OS and PFS for comparing prognosis between the two groups.

Results

In this study, 36 cases (50.00%) were included in the cholecystectomy group and 36 cases (50.00%) were included in the non-cholecystectomy group. Median OS was 35.55 months (4.20-36.00 months) in the cholecystectomy group and 31.19 months (10.80-36.00 months) in the non-cholecystectomy group (P=0.894 months). The mortality rates in the cholecystectomy group and the non-cholecystectomy group were 22.22% and 22.22%, respectively. The 1-year, 2-year, and 3-year cumulative OS rates were 91.67%, 79.91% and 75.71% respectively in the cholecystectomy group, and 97.22%, 88.72% and 73.81% respectively in the non-cholecystectomy group (P=0.97). The median PFS was 7.67 months (1.68-32.30 months) in the cholecystectomy group and 18.25 months (2.24-33.60 months) in the non-cholecystectomy group (P<0.01). The recurrence rates of HCC in the cholecystectomy group and the non-cholecystectomy group were 69.44% and 91.67%, respectively; the 1-year, 2-year and 3-year cumulative progression-free survival rates in the cholecystectomy group were 36.11%, 16.67% and 0.00%, respectively; and the non-cholecystectomy group were 77.78%, 46.89% and 0.00%, respectively. The cumulative PFS rate in the non-cholecystectomy group was significantly higher than that in the cholecystectomy group (P<0.01). Multivariate analysis showed that number of tumor=3 (HR=18.91, 95%CI:1.54-232.99, P=0.02) was an independent risk factor associated with OS. Multivariate analysis showed that cholecystectomy (HR=3.55, 95%CI:1.74-7.26, P<0.01), number of tumor=2 or 3 (HR=2.21, 95%CI:1.10-4.42, P=0.02; HR=3.63, 95%CI:1.26-10.45, P=0.02) and AFP≥400 ng/mL (HR=0.43, 95%CI:0.19-0.98, P<0.05) were independent risk factors associated with PFS.

Conclusions

Patients with HCC receiving MWA are more likely to have intrahepatic recurrence after cholecystectomy and this could be related to elevated γ-GT levels , and the recurrence rate increases with time.

Key words: Hepatocellular carcinoma, Microwave ablation, Cholecystectomy, Prognostic analysis
表1 纳入患者的基线特征
患者 例数 未切除组 切除组 P值
36(50.00%) 36(50.00%)
年龄（岁）   59.92±10.40 59.17±8.09 0.73
性别        
  男 61 30(83.33%) 31(86.11%) 0.74
  女 11 6(16.67%) 5(13.89%)
最大直径（cm）   1.70±0.43 1.85±0.53 0.20
肿瘤数量        
  1 22 11(30.56%) 11(30.56%) 0.82
  2 36 17(47.22%) 19(52.78%)
  3 14 8(22.22%) 6(16.67%)
HBV        
  是 62 32(88.89%) 32(88.89%) 1.00
  否 8 4(11.11%) 4(11.11%)
Child分级        
  A 71 36(100.00%) 35(97.22%) 0.31
  B 1 0(0.00%) 1(2.78%)
AFP（ng/mL）        
  ≤400 53 28(77.78%) 25(69.44%) 0.42
  >400 19 8(22.00%) 11(30.56%)
AST（U/L）   24.78±6.59 21.14±6.41 0.02
ALT（U/L）   24.61±13.20 23.55±11.99 0.72
GT（U/L）   56.86±50.85 44.12±30.70 0.20
TBIL（μmol/L）   15.45±10.05 13.86±7.10 0.44
图1 非胆囊切除组和胆囊切除组之间的总生存率（1A）和无进展生存率（1B）
表2 总生存率相关危险因素的Cox分析
患者 单因素分析 多因素分析
HR 95%CI P值 HR 95%CI P值
年龄（岁） 1.03 0.97～1.008 0.34 1.05 0.99～1.12 0.12
性别            
  男 2.88 0.38～21.85 0.31 1.11 0.11～10.64 0.93
  女 1.00     1.00    
胆囊切除            
  是 1.02 0.38～2.72 0.97 1.06 0.30～3.77 0.93
  否 1.00     1.00    
最大直径（cm） 1.40 0.50～3.92 0.52 5.02 0.80～31.55 0.09
数量            
  1 1.00     1.00    
  2 1.55 0.41～5.87 0.52 1.96 0.35～11.003 0.45
  3 2.92 0.70～12.23 0.14 18.91 1.54～232.99 0.02
AFP（ng/mL）            
  < 400 1.00     1.00    
  ≥400 0.98 0.32～3.05 0.98 0.72 0.17～3.00 0.65
HBV            
  是 0.39 0.11～1.37 0.14 0.27 0.06～1.28 0.10
  否 1.00     1.00    
Child分级            
  A 1.00     1.00    
  B 3.63 0.48～27.55 0.21 16.40 0.92～293.63 0.06
ALT（U/L） 1.00 0.96～1.04 0.99 0.99 0.92～1.006 0.72
AST（U/L） 1.01 0.94～1.08 0.87 0.97 0.85～1.10 0.63
γ-GT（U/L） 1.00 1.00～1.01 0.35 1.01 1.00～1.02 0.11
TBIL（ng/mL） 1.00 0.95～1.06 0.99 1.02 0.95～1.11 0.55
表3 无进展生存率相关危险因素的Cox分析
患者 单因素分析 多因素分析
HR 95%CI P值 HR 95%CI P值
年龄（岁） 1.00 0.98～1.004 0.59 0.99 0.96～1.002 0.57
性别            
  男 1.76 0.79～3.90 0.16 0.98 0.34～2.80 0.96
  女 1.00     1.00    
胆囊切除            
  是 2.42 1.41～4.14 <0.01 3.55 1.74～7.26 <0.01
  否 1.00     1.00    
最大直径（cm） 1.83 0.98～3.40 0.06 2.47 1.005～5.84 0.04
数量            
  1 1.00     1.00    
  2 1.55 0.83～2.90 0.17 2.21 1.10～4.42 0.02
  3 1.57 0.73～3.37 0.25 3.63 1.26～10.45 0.02
AFP（ng/mL）            
  < 400 1.00     1.00    
  ≥400 0.91 0.50～1.67 0.77 0.43 0.19～0.98 0.05
HBV            
  是 0.74 0.29～1.90 0.54 0.69 0.23～2.06 0.50
  否 1.00     1.00    
Child分级            
  A 1.00     1.00    
  B 2.56 0.35～18.97 0.36 2.22 0.25～19.69 0.48
ALT（U/L） 1.00 0.98～1.03 0.80 0.97 0.94～1.00 0.06
AST（U/L） 1.00 0.96～1.00 0.80 1.00 0.97～1.11 0.28
γ-GT（U/L） 1.00 1.00～1.01 0.08 1.00 1.00～1.02 0.07
TBIL（ng/mL） 0.98 0.95～1.01 0.20 1.00 0.96～1.04 0.97
图2 不同肿瘤数量亚组之间的总生存率
图3 不同AFP水平亚组之间的无进展生存率
图4 不同肿瘤数量亚组之间的无进展总生存率
[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. DOI: 10.3322/caac.21551
[2]
Zheng R, Qu C, Zhang S, et al. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030[J]. Chin J Cancer Res, 2018, 30(6): 571-579. DOI: 10.21147/j.issn.1000-9604.2018.06.01
[3]
Moris D, Vernadakis S, Papalampros A, et al. The effect of Guidelines in surgical decision making: The paradigm of hepatocellular carcinoma[J]. J BUON, 2016, 21(6): 1332-1336. DOI:
[4]
Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma[J]. Hepatol Int, 2010, 4(2): 439-474. DOI: 10.1007/s12072-010-9165-7
[5]
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2): 723-750. DOI: 10.1002/hep.29913
[6]
European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J].J Hepatol, 2012, 56(4): 908-943. DOI: 10.1016/j.jhep.2011.12.001
[7]
Benson AB, 3rd, D'Angelica MI, Abbott DE, et al. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017[J].J Natl Compr Canc Netw, 2017, 15(5): 563-573. DOI:
[8]
Wood R, Fraser LA, Brewster DH, et al. Epidemiology of gallbladder cancer and trends in cholecystectomy rates in Scotland, 1968-1998[J]. Eur J Cancer, 2003, 39(14): 2080-2086. DOI:
[9]
Li Y, He R, Chen S, et al. Effect of dexmedetomidine on early postoperative cognitive dysfunction and peri-operative inflammation in elderly patients undergoing laparoscopic cholecystectomy[J]. Exp Ther Med, 2015, 10(5): 1635-1642. DOI: 10.3892/etm.2015.2726
[10]
Madureira FA, Manso JE, Madureira Filho D, et al. Inflammation in laparoendoscopic single-site surgery versus laparoscopic cholecystectomy[J]. Surg Innov, 2014, 21(3): 263-268. DOI: 10.1177/1553350613499454
[11]
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis[J]. Gastroenterology, 2007, 132(7): 2557-2576. DOI: 10.1053/j.gastro.2007.04.061
[12]
Tarao K, Hoshino H, Shimizu A, et al. Role of increased DNA synthesis activity of hepatocytes in multicentric hepatocarcinogenesis in residual liver of hepatectomized cirrhotic patients with hepatocellular carcinoma[J]. Jpn J Cancer Res, 1994, 85(10): 1040-1044. DOI: 10.1111/j.1349-7006.1994.tb02903.x
[13]
Nogueira L, Freedman ND, Engels EA, et al. Gallstones, cholecystectomy, and risk of digestive system cancers[J]. Am J Epidemiol, 2014, 179(6): 731-739. DOI: 10.1093/aje/kwt322
[14]
Lagergren J, Mattsson F, El-Serag H, et al. Increased risk of hepatocellular carcinoma after cholecystectomy[J]. Br J Cancer, 2011, 105(1): 154-156. DOI: 10.1038/bjc.2011.181
[15]
Guo L, Mao J, Li Y, et al. Cholelithiasis, cholecystectomy and risk of hepatocellular carcinoma: a meta-analysis[J]. J Cancer Res Ther, 2014, 10(4): 834-838. DOI: 10.4103/0973-1482.135992
[16]
Li T, Wang SK, Zhi XT, et al. Cholecystectomy is associated with higher risk of early recurrence and poorer survival after curative resection for early stage hepatocellular carcinoma[J]. Sci Rep, 2016, 6: 28229. DOI: 10.1038/srep28229
[17]
Yu J, Yu XL, Han ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial[J]. Gut, 2017, 66(6): 1172-1173. DOI: 10.1136/gutjnl-2016-312629
[18]
Kao WY, Hwang CY, Su CW, et al. Risk of hepato-biliary cancer after cholecystectomy: a nationwide cohort study[J]. J Gastrointest Surg, 2013, 17(2): 345-351. DOI: 10.1007/s11605-012-2090-4
[19]
Triolo M, Della Corte C, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma[J]. Liver Int, 2014, 34 Suppl 1: 139-145. DOI: 10.1111/liv.12394
[20]
Yu L, Cheng YJ, Cheng ML, et al. Quantitative assessment of common genetic variations in HLA-DP with hepatitis B virus infection, clearance and hepatocellular carcinoma development[J]. Sci Rep, 2015, 5: 14933. DOI: 10.1038/srep14933
[21]
Wang Q, Blank S, Fiel MI, et al. The Severity of Liver Fibrosis Influences the Prognostic Value of Inflammation-Based Scores in Hepatitis B-Associated Hepatocellular Carcinoma[J]. Ann Surg Oncol, 2015, 22 Suppl 3: S1125-1132. DOI: 10.1245/s10434-015-4598-9
[22]
Aravalli RN, Greten TF. FoxC1: Novel Regulator of Inflammation-Induced Metastasis in Hepatocellular Carcinoma[J]. Gastroenterology, 2015, 149(4): 861-863. DOI: 10.1053/j.gastro.2015.08.032
[23]
Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study[J]. J Clin Oncol, 2002, 20(7): 1775-1785. DOI: 10.1200/JCO.2002.07.089.
[1] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[2] 李晓玉, 江庆, 汤海琴, 罗静枝. 围手术期综合管理对胆总管结石并急性胆管炎患者ERCP +LC术后心肌损伤的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 57-60.
[3] 甄子铂, 刘金虎. 基于列线图模型探究静脉全身麻醉腹腔镜胆囊切除术患者术后肠道功能紊乱的影响因素[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 61-65.
[4] 鲁鑫, 许佳怡, 刘洋, 杨琴, 鞠雯雯, 徐缨龙. 早期LC术与PTCD续贯LC术治疗急性胆囊炎对患者肝功能及预后的影响比较[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 648-650.
[5] 张建波, 东爱华. 不同腹腔镜手术治疗胆囊结石合并胆总管结石的疗效及并发症对比[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 693-696.
[6] 易明超, 汪鑫, 向涵, 苏怀东, 张伟. 一种T型记忆金属线在经脐单孔腹腔镜胆囊切除术中的临床应用[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 599-599.
[7] 易明超, 汪鑫, 向涵, 苏怀东, 张伟. 一种T型记忆金属线在经脐单孔腹腔镜胆囊切除术中的临床应用[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 599-599.
[8] 牛朝, 李波, 张万福, 靳文帝, 王春晓, 李晓刚. 腹腔镜袖状胃切除联合胆囊切除治疗肥胖合并胆囊结石安全性和疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 635-639.
[9] 张文华, 陶焠, 胡添松. 不同部位外生型肝癌临床病理特点及其对术后肝内复发和预后影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 651-655.
[10] 韩冰, 顾劲扬. 深度学习神经网络在肝癌诊疗中的研究及应用前景[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 480-485.
[11] 周后平, 袁源, 欧廷政, 李贝贝, 尚明铭, 姚本能, 宋新, 罗雪梅. 胆囊板Laennec膜间隙逆行分离联合Pringle法在困难胆囊LC术中应用（附视频）[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 540-544.
[12] 张海涛, 贾哲, 马超, 张其坤, 武聚山, 郭庆良, 曾道炳, 栗光明, 王孟龙. 手术切除与射频消融治疗血管周围型单发小肝癌临床疗效分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 523-527.
[13] 李翠平, 陈晓燕, 钱师宇, 林惠珠, 曾彩辉, 阳莉, 卢建溪. 不同抗凝剂保存液对脐血培养的NK细胞增殖及杀伤效应的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 572-576.
[14] 萨仁高娃, 张英霞, 邓伟, 闫诺, 樊宁. 超声引导下鼠肝消融术后组织病理特征的变化规律及影响[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 394-398.
[15] 郭震天, 张宗明, 赵月, 刘立民, 张翀, 刘卓, 齐晖, 田坤. 机器学习算法预测老年急性胆囊炎术后住院时间探索[J]. 中华临床医师杂志(电子版), 2023, 17(9): 955-961.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号